The Scientist

» chemistry, disease/medicine and culture

Most Recent

image: Transparency Now

Transparency Now

By | May 1, 2016

Science is messy. So lay it out, warts and all.

1 Comment

Science is messy. So lay it out, warts and all.

0 Comments

image: Capsule Reviews

Capsule Reviews

By | May 1, 2016

Science is messy. So lay it out, warts and all.

0 Comments

image: Contributors

Contributors

By and | May 1, 2016

Science is messy. So lay it out, warts and all.

0 Comments

image: Speaking of Science

Speaking of Science

By | May 1, 2016

Science is messy. So lay it out, warts and all.

0 Comments

image: The Global Science Era

The Global Science Era

By | May 1, 2016

Science is messy. So lay it out, warts and all.

2 Comments

image: The Zombie Literature

The Zombie Literature

By | May 1, 2016

Science is messy. So lay it out, warts and all.

9 Comments

image: To Each Animal Its Own Cognition

To Each Animal Its Own Cognition

By | May 1, 2016

Science is messy. So lay it out, warts and all.

3 Comments

image: Antibodies Prevent HIV Infection in Monkeys

Antibodies Prevent HIV Infection in Monkeys

By | April 29, 2016

Science is messy. So lay it out, warts and all.

0 Comments

image: “Hunger Hormone” No More?

“Hunger Hormone” No More?

By | April 20, 2016

Science is messy. So lay it out, warts and all.

3 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech